Collecting cancer-related data and samples for personalized medicine
Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership With Patients
This study is collecting blood, tissue, and other samples from cancer patients and those at risk to see how this information can help create more personalized treatments for cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Southern California Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT02970045 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a comprehensive repository of biological samples and clinical information from patients with cancer or those at risk for cancer. It involves collecting blood, tissue, and other biological samples during routine care visits and surgeries, alongside gathering detailed patient data through surveys. The goal is to establish a longitudinal study that follows patients throughout their lives, linking clinical data with biospecimens to enhance understanding of cancer treatment responses and facilitate personalized medicine. Patients will be periodically followed up after the study's completion.
Who should consider this trial
Good fit: Ideal candidates are patients registered for outpatient or inpatient care at the University of Southern California Norris Comprehensive Cancer Center.
Not a fit: Patients who are not registered at USC Norris or cannot provide informed consent in English or Spanish may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized cancer treatments based on individual genetic and clinical profiles.
How similar studies have performed: Other studies utilizing similar biospecimen collection and data integration approaches have shown promise in advancing personalized medicine, indicating a potential for success in this study as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Limited to those patients who are registered for outpatient or inpatient care at University of Southern California (USC) Norris * Able to understand and sign the TCCP informed consent, California subject's bill of rights, Health Insurance Portability and Accountability Act (HIPAA), and research authorization form directly or through an authorized representative; the informed consent, subject's bill of rights, HIPAA, and research authorization will be available in both English and Spanish languages Exclusion Criteria: * Individuals who are not registered as patients for outpatient or inpatient care at USC Norris * Individuals who are unable to understand or sign the TCCP informed consent, subject's bill of rights, HIPAA, and research authorization in either English or Spanish
Where this trial is running
Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Bodour Salhia, PhD — University of Southern California
- Study coordinator: Melissa Woodhouse, MHA, MPH
- Email: Melissa.woodhouse@med.usc.edu
- Phone: 323-865-0489
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.